SCHEMBL4868133

SCHEMBL4868133

CC(C)Cn1c(-c2cnn(-c3ccccc3)c2)c([N+](=O)[O-])c(=O)n(C(C)c2ccccc2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.43
ADORA1 P30542 5/20 0.37
ADORA2B P29275 5/20 0.37
ADORA2A P29274 4/20 0.37
DCTPP1 Q9H773 1/20 0.36
ADORA3 P0DMS8 4/20 0.36
KDM5B Q9UGL1 1/20 0.35
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM5A P29375 1/20 0.33
CREBBP Q92793 2/20 0.32
GRM4 Q14833 2/20 0.32
MAPT P10636 2/20 0.32
CYP1A2 P05177 2/20 0.32
HPGD P15428 2/20 0.32
CYP2C19 P33261 2/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866000 0.90 HSP90AA1 (0.47) HSP90AA1ADORA1ADORA2BADORA2AADORA3
SCHEMBL4863582 0.89 DCTPP1 (0.37) ADORA1ADORA2BADORA2ADCTPP1ADORA3
SCHEMBL4859896 0.88 HSP90AA1 (0.47) HSP90AA1ADORA1ADORA2BADORA2ADCTPP1
SCHEMBL4868140 0.83 ADORA1 (0.42) HSP90AA1ADORA1ADORA2BADORA2AADORA3
SCHEMBL4793242 0.83 SMN1; SMN2 (0.37) HSP90AA1DCTPP1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL4868150 0.83 HSP90AA1 (0.43) HSP90AA1ADORA1ADORA2BADORA2AADORA3
SCHEMBL4866844 0.82 ADORA1 (0.44) HSP90AA1ADORA1ADORA2BADORA2AADORA3
SCHEMBL4865952 0.82 ADORA2B (0.41) ADORA1ADORA2BADORA2AADORA3ALDH1A1
SCHEMBL4896986 0.80 ADORA2B (0.43) ADORA1ADORA2BADORA2AADORA3ALDH1A1
SCHEMBL4863917 0.79 ADORA2B (0.46) HSP90AA1ADORA1ADORA2BADORA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 HSP90AA1 1863/4885ADORA1 4/4885ADORA2B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.